News Release

Multiclonality of estrogen receptor expression in ductal carcinoma in situ (DCIS)

Peer-Reviewed Publication

Impact Journals LLC

Figure 1

image: Figure 1: Multi-clonal ER expression in DCIS. view more 

Credit: 2023 Thorat.

“We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.”

BUFFALO, NY- August 1, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “Multiclonality of ER expression in DCIS – Implications for clinical practice and future research.”

Estrogen receptor (ER) expression is not routinely evaluated in ductal carcinoma in situ (DCIS). This may be because the prognostic role of ER in DCIS was unclear until the UK/ ANZ DCIS trial in 2021 showed that lack of ER expression in DCIS was associated with a greater than 3-fold risk of ipsilateral recurrence. This was the largest (to date) case-control study nested in a DCIS randomized trial. 

The meticulous study design eliminated treatment allocation bias as well as treatment-related confounding. This was also the first-ever study to show that ER expression in DCIS is multi-clonal — having very important clinical and research implications. A small proportion of otherwise ER-positive DCIS also contained carcinoma in situ (CIS) duct/s that completely lacked ER expression. 

“This admixture of clearly ER-positive and ER-negative ducts is not the same as heterogeneity in ER expression and I labeled such DCIS cases as multiclonal DCIS even if just one CIS duct in the entire section lacked ER expression.”

In his new editorial, Dr. Mangesh A. Thorat from Guy's and St Thomas' NHS Foundation Trust, Queen Mary University of London and King's College London discusses this study in greater detail, the clinical implications of ER status in DCIS, the potential for avoiding overtreatment and undertreatment based on ER expression, and the importance of simple clinical observations in research.

“In summary, ER is a strong and independent prognostic biomarker in DCIS and our novel clonal method is a more accurate method to assess ER status in DCIS.”

Read the full editorial: DOI: 

Correspondence to: Mangesh A. Thorat


Keywords: ductal carcinoma in situ (DCIS), invasive breast cancer, ER, recurrence, clonality 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit and connect with us on social media:


Sign up for free Altmetric alerts about this article:

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact:


Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.